Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals (CRVS) is a clinical-stage biopharmaceutical company advancing novel immunotherapies targeting T cell modulation through ITK inhibition. This page provides investors and industry stakeholders with timely updates on CRVS’s clinical developments, regulatory milestones, and strategic initiatives.
Access the latest press releases, earnings reports, and research updates in one centralized location. Track progress across the company’s pipeline, including soquelitinib for T cell lymphomas and autoimmune conditions, as well as collaborations shaping its therapeutic platform.
Key updates include clinical trial results, partnership announcements, and financial performance. Bookmark this page to stay informed about CRVS’s advancements in immuno-oncology and immune-mediated disease research. Visit regularly for authoritative insights into the company’s scientific and operational progress.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis. The trial's lowest dose cohort demonstrated favorable safety and efficacy profiles. Key findings include:
- Mean EASI score reduction of 55.9% at 28 days and 69.1% at 58 days in the treatment group, compared to 27.0% and 19.1% in placebo
- Nine of 12 patients achieved EASI 50 at day 28, with three achieving EASI 75 and one reaching EASI 90
- No significant safety issues were observed during the trial
Additionally, Samlyn Capital exercised warrants to purchase 3,633,978 shares, providing approximately $12.7 million in cash proceeds to Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced it will release interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis on December 18, 2024. The trial is a randomized, double-blind, placebo-controlled study evaluating the drug in patients with moderate to severe atopic dermatitis. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to present the data, which will also be released via press release. The presentation will include slides and be accessible through a toll-free domestic line or international dial-in, with a webcast replay available on the company's website for 60 days.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced the publication of preclinical data for soquelitinib, their lead ITK inhibitor program, in npj Drug Discovery. The research demonstrates soquelitinib's potential as a novel approach to modulate tumor immunity through its mechanism of action - suppressing Th2 and Th17 cytokine production while sparing Th1 cytokines.
The data shows that soquelitinib increases effector function of cytotoxic CD8 positive T cells and enhances memory T cell function. The company is currently conducting a Phase 3 clinical trial for relapsed peripheral T cell lymphoma (PTCL) and a Phase 1 trial for atopic dermatitis, with plans to initiate another Phase 1 trial in solid tumors.
Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib treatment, mice showed significant reduction in lung infiltration and fibrosis, improved clinical scores, reduced vascular smooth muscle hypertrophy, and lower right ventricular systolic blood pressure. These results were validated in a second bleomycin lung injury model.
Corvus Pharmaceuticals provided Q3 2024 updates on its clinical programs. The company is advancing two clinical trials for soquelitinib: a Phase 3 trial in Peripheral T Cell Lymphoma (PTCL) and a Phase 1 trial in atopic dermatitis, with interim data expected in December 2024. Financial highlights include cash position of $41.7M as of September 30, 2024, with an additional $5.9M from warrant exercises in October. Q3 net loss was $40.2M, including a $32.8M non-cash warrant liability loss. R&D expenses increased to $5.2M from $4.0M year-over-year. The company expects current cash to fund operations into 2026.
Corvus Pharmaceuticals (NASDAQ: CRVS) presented new data at SITC's 39th Annual Meeting showing ciforadenant's potential to overcome resistance to anti-PD1 immunotherapy in metastatic castration resistant prostate cancer (mCRPC). The research, selected as a Top 100 abstract, identified SPP1+ myeloid cells as critical mediators of immunotherapy resistance. Clinical trial results showed that when ciforadenant was combined with atezolizumab, 5 of 24 patients (21%) achieved PSA partial responses, compared to 1 of 11 (9%) with ciforadenant monotherapy. The study demonstrated that ciforadenant treatment reduced immunosuppression and enhanced sensitivity to anti-PD1 therapy.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced it will host a conference call and webcast on November 12, 2024 at 4:30 pm ET to provide a business update and report third quarter 2024 financial results. The conference call can be accessed toll-free at 1-800-717-1738 (domestic) or 1-646-307-1865 (international). A live webcast will be available through the company's investor relations section, with a replay accessible for 90 days on Corvus' website.
Corvus Pharmaceuticals (NASDAQ: CRVS) has initiated a registrational Phase 3 clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). Soquelitinib, a potential first-in-class ITK inhibitor, has been granted Orphan Drug Designation and Fast Track Designation by the FDA. The trial will enroll approximately 150 patients across 40 sites in the US, Canada, Australia, and South Korea.
The randomized, controlled study will compare soquelitinib to standard chemotherapy, with a primary endpoint of progression-free survival. Soquelitinib's unique mechanism of action, based on selective ITK inhibition, shows potential for treating T cell lymphomas, solid tumors, and immune diseases. This trial marks a significant milestone for Corvus and PTCL patients, as there are currently no fully approved agents for relapsed PTCL treatment.
Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9-11, 2024. Richard A. Miller, M.D., president and CEO, and Jeffrey Arcara, chief business officer, will represent the company.
Key points:
- One-on-one meetings with investors scheduled
- Corporate overview presentation on September 10 at 12:00pm ET
- Live webcast available, accessible for 90 days post-event
- Webcast link provided in the investor relations section of Corvus website
This conference participation highlights Corvus Pharmaceuticals' efforts to engage with investors and showcase their latest developments in the biopharmaceutical industry.
Corvus Pharmaceuticals (CRVS) provided a Q2 2024 business update, highlighting progress in its soquelitinib (ITK inhibitor) program. Early results from the Phase 1 trial in atopic dermatitis showed clinical activity and cytokine changes consistent with ITK inhibition. The company is advancing toward initial enrollment in a Phase 3 trial for peripheral T cell lymphoma (PTCL) in Q3 2024. In the ongoing Phase 1/1b PTCL trial, soquelitinib demonstrated a 39% objective response rate, including 26% complete responses. Corvus reported $47.2 million in cash as of June 30, 2024, expecting to fund operations into Q4 2025. The company anticipates 2024 net cash used in operating activities between $24-$27 million.
FAQ
What is the current stock price of Corvus Pharmaceu (CRVS)?
What is the market cap of Corvus Pharmaceu (CRVS)?
